-
Belimumab: Unveiling Its Role in Lupus and Beyond(Post)
Quick Facts About BelimumabWhat is Belimumab?Belimumab is a monoclonal antibody used to treat systemic lupus erythematosus (SLE), an autoimmune disease. It is marketed under the brand na
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Canakinumab: Unraveling Its Role in Inflammatory Disease and Cancer Research(Post)Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various disease
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect
Nadecnemab: Advancing Cancer Research Through Anti-CD47 Targeting(Post)Quick Facts About NadecnemabWhat is Nadecnemab?Nadecnemab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint protein involved in cancer evasion.How Does
Bermekimab: Unveiling the Role of Anti-CD47 in Hidradenitis Suppurativa and Atopic Dermatitis(Post)What You Need to Know About BermekimabWhat is Bermekimab?Bermekimab is a monoclonal antibody targeting the CD47 receptor, developed to modulate the immune system and improve conditions l
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
The role of IL-18 in health and disease(Post)Exploring IL-18: A key cytokine in inflammation and disease. Key Takeaways: IL-18, a pro-inflammatory cytokine, plays a pivotal role in immune responses, particularly in inducing Type II
Enhancing Cancer Research: Syngeneic Mouse Models and Immune Checkpoint Inhibitors(Post)Enhancing Cancer Research: Syngeneic Mouse Models and Immune Checkpoint Inhibitors A quick guide to Syngeneic Mouse Models Syngeneic Mouse Models Cancer research has seen rema
Litifilimab: A Promising Anti-BDCA2 Antibody for Lupus Treatment(Post)Quick Facts About LitifilimabWhat is Litifilimab?Litifilimab is a monoclonal antibody developed by Biogen targeting BDCA2, a receptor on plasmacytoid dendritic cells (pDCs), to regulate
Tomaralimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About TomaralimabWhat is Tomaralimab?Tomaralimab is an anti-CD47 monoclonal antibody designed to enhance immune system recognition of cancer cells by blocking the "don't eat
Obinutuzumab: Advancing Targeted Therapy in Hematologic Cancers(Post)Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem
T Cell Types, Activation, Polarization & Function(Post)T Cell Types, Activation, Polarization & Function A comprehensive guide to T cells! Introduction T-cells, vital components of the immune system, encompass vari
Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and Beyond(Post)What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destructio
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers